Ildstad Suzanne

DirectorTalaris Therapeutics, Inc. (TALS) · full profile →Form 4 · filed Apr 19, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$319K
Net Open-Market Flow
-$319K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 18, 2023Sell(S)49K$2.15$106K2.9M
Apr 17, 2023Sell(S)100K$2.14$214K3.0M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-024771) within minutes of acceptance. Every field above traces to the original document. Verify it directly: